Clinical Trials Logo

Acute Kidney Failure clinical trials

View clinical trials related to Acute Kidney Failure.

Filter by:

NCT ID: NCT00890214 Completed - Clinical trials for Acute Kidney Failure

Prostacyclin's Effect on Platelet Responsiveness

Start date: September 2007
Phase: Phase 4
Study type: Interventional

The researchers investigated the influence of a prostacyclin analogue (PGIA) versus unfractionated heparin (UFH) on ex vivo platelet function, during continuous venovenous hemodiafiltration.

NCT ID: NCT00877370 Completed - Clinical trials for Acute Kidney Failure

Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis

Start date: February 2009
Phase: Phase 4
Study type: Interventional

Critically ill patients in the intensive care unit often receive continuous hemodialysis to treat their kidney failure. Ertapenem is an antibiotic often used in these patients. Continuous dialysis may remove ertapenem, putting patients at risk for inappropriate treatment of their infection. This study will determine how much ertapenem is removed by continuous hemodialysis.

NCT ID: NCT00736866 Completed - Clinical trials for Acute Kidney Failure

The Acetylcysteine for Contrast-Induced Nephropathy Trial

ACT
Start date: August 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of acetylcysteine compared to placebo for the contrast-induced nephropathy prevention, between 48 and 96 hours after procedures that use contrast. Contrast-induced nephropathy is defined as an increase of 25% in serum creatinine before the procedure.

NCT ID: NCT00673244 Completed - Clinical trials for Acute Kidney Failure

Protocol to Assess the Severity of Acute Kidney Injury

AKI
Start date: April 2008
Phase: N/A
Study type: Interventional

The principal objective is to safely determine if we can identify the severity of Acute Kidney Injury (AKI) early in the course of the disease. Once enrolled, we will draw blood and urine for relevant biomarkers. Our goal is to validate if any of these biomarkers can predict the course of AKI (recovery v. RRT v. death)

NCT ID: NCT00529139 Completed - Clinical trials for Acute Kidney Failure

Hannover Dialysis Outcome Study

HAND-OUT
Start date: July 2003
Phase: Phase 4
Study type: Interventional

Mortality rates of patients with acute kidney injury in the intensive care unit have changed little over the past few decades despite significant advances in supportive care. Few interventions have been shown to result in an improvement of in-hospital mortality of these patients, with dose of renal replacement therapy (RRT) being one of the most important. Patients undergoing continuous veno-venous hemofiltration had better outcomes with ultrafiltration rates of 35 mL/kg/h or 45 mL/kg/h than those treated at a rate of 20 mL/kg/h. In a different trial, intermittent hemodialysis on a daily basis resulted in better control of uremia, fewer hypotensive episodes during dialysis, and more rapid resolution of acute renal failure than thrice weekly hemodialysis. In the present study we examine survival and renal recovery in critically ill patients with acute kidney injury that are treated with a currently recommended (standard) dose of RRT, and patients that receive intensified RRT.

NCT ID: NCT00472563 Completed - Clinical trials for Acute Kidney Failure

Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate

PROMEC
Start date: May 2007
Phase: Phase 2/Phase 3
Study type: Interventional

Deterioration of kidney renal function occurs in a minority of people due to contrast-required procedures. The purpose of this study is to compare two different interventions to reduce the risk of kidney injury after contrast medium exposition. We will perform a randomized clinical trial following a modification of a previously published protocol (Merten et al.JAMA 2004;291(19):2328-34). Patients will be randomly assigned to one of two groups of treatment. Group A will receive 1 cc/kg/hour of 0.9% saline infusion starting 12 hours before and continuing 12 hours after the procedure. Group B will receive 3 cc/kg of sodium bicarbonate solution for one hour prior to procedure, then drip rate will be decreased to 1 cc/kg/hour until 6 hours post procedure.

NCT ID: NCT00252200 Completed - Clinical trials for Acute Kidney Failure

BNP (Nesiritide) vs. Placebo to Protect Kidney Function in Patients Undergoing Heart Bypass Surgery.

Start date: March 2003
Phase: Phase 1/Phase 2
Study type: Interventional

Use of BNP (nesiritide) vs placebo to help protect kidney function in patients undergoing heart bypass surgery.